Ibutamoren
Grundinformationen
- CAS
159634-47-6- Standard-SMILES
CC(C)(N)C(=O)N[C@H](COCc1ccccc1)C(=O)N1CCC2(CC1)CN(S(C)(=O)=O)c1ccccc12- InChIKey
UMUPQWIGCOZEOY-JOCHJYFZSA-N- Summenformel
- C27H36N4O5S
- Durchschnittliche Molmasse
- 528,7 g/mol
- Monoisotopische Masse
- 528,24064144
Überblick
Ibutamoren is an orally bioavailable, small molecule, non-peptide growth hormone secretagogue (GHS). Upon administration, ibutamoren promotes the release of growth hormone (GH) from the pituitary gland, thereby increasing plasma GH levels. This may counteract GH deficiency. GH plays an important role in many biological processes.
Namen und Bezeichner
- Bevorzugter Name
- Ibutamoren
- IUPAC
- 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
- Englischer Name
- MK-677
- Summenformel
- C27H36N4O5S
- Molmasse
- 528.66
Namen und Synonyme
Ibutamoren159634-47-6ibutamorenoGJ0EGN38ULL 1631912-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamideL-163,191DTXSID901667002-AMINO-N-((R)-2-(BENZYLOXY)-1-((1-(METHYLSULFONYL)SPIRO(INDOLINE-3,4'-PIPERIDIN)-1'-YL)CARBONYL)ETHYL)-2-METHYLPROPIONAMIDE2-AMINO-N-(3-(BENZYLOXY)-1-(1-METHANESULFONYL-1,2-DIHYDROSPIRO(INDOLE-3,4'-PIPERIDIN)-1'-YL)-1-OXOPROPAN-2-YL)-2-METHYLPROPANAMIDEibutamorenum2-amino-2-methyl-N-((2R)-1-(1-methylsulfonylspiro(2H-indole-3,4'-piperidine)-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl)propanamide
Weitere Namen anzeigen
IbutaMoren (MK-677)MK-677Mk677 SarmsMK-0677MK-677Ibutamoren, 10 mM in DMSOIBUTAMOREN (MK-677), CID178024MK-677?/?Ibutamoren 10mg TabletsIbutamoren,MK-677, MK-0677, L-163,191Ibutamoren mesylate (MK-0667, L163191)
RefChem:55388DTXCID0089191Ibutamoren [INN]CHEMBL13817(R)-2-amino-N-(3-(benzyloxy)-1-(1-(methylsulfonyl)spiro[indoline-3,4'-piperidin]-1'-yl)-1-oxopropan-2-yl)-2-methylpropanamide192511-65-2MK-677, (HCl salt)CHEMBL542653
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 1,3
- Polarare Oberfläche (TPSA)
- 130 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 7
- Frei drehbare Bindungen
- 8
- Schwere Atome
- 37
- Formalladung
- 0
- Komplexität
- 920
Experimentelle und physikochemische Eigenschaften
LogP2.37
Physikochemische Eigenschaften
- Dichte
- 1.32 · 1.32
- pka
- 15.73 · 15.73±0.46(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to off-white
- InChIKey
- UMUPQWIGCOZEOY-JOCHJYFZSA-N
- SMILES
- C(N[C@H](COCC1=CC=CC=C1)C(N1CCC2(CC1)C1=C(N(S(C)(=O)=O)C2)C=CC=C1)=O)(=O)C(N)(C)C
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Danger
H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]
P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory.
Gefahrenhinweise
Hazard Classes and CategoriesAcute Tox. 3 (100%)
Sicherheitsdaten
- Alarmwort
- Achtung
- Gefahrenhinweise
- Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H301
Chemie und Industrie
Anwendungen
BeschreibungIbutamoren (INN) (developmental code names MK-677, MK-0677, L-163,191)is a non-peptidic, potent, long acting, orally-active, and selective agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including GH and insulin-like growth factor 1 (IGF-1), but without affecting cortisol levels. MK677 has shown to sustain activation of GH-IGF-1 Axis and increase in lean body mass but no change in total fat mass or visceral fat. It is currently under development as a potential treatment for reduced levels of these hormones, such as in children or elderly adults with growth hormone deficiency, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty in the elderly.
VerwendenGrowth hormone releasing factor.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…